Mitoxantrone

• Description:

  Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity[1][2][3][4]. Mitoxantrone also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively[5].

• Product Name Alternative:

  Mitozantrone; NSC 301739

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; Endogenous Metabolite; Orthopoxvirus; PKC; Topoisomerase

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; TGF-beta/Smad

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/mitoxantrone.html

• Concentration:

  10mM

• Purity:

  99.58

• Solubility:

  DMSO : 35 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C1C2=C(C(NCCNCCO)=CC=C2NCCNCCO)C(C3=C(O)C=CC(O)=C13)=O

• Molecular Formula:

  C22H28N4O6

• Molecular Weight:

  444.48

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Takeuchi N, et al. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem. 1992 Dec;112 (6) :762-7.|[2]Bellosillo B, et al. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100 (1) :142-6.|[3]Vibet S, et al. Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines. Drug Metab Dispos. 2007 May;35 (5) :822-8.|[4]Fujimoto S, et al. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol. 1982;8 (2) :157-62.|[5]Sharon E Altmann, et al. Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone. Antiviral Res. 2012 Feb;93 (2) :305-308.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  PKC; Topo II

• Citation 01:

  Acta Pharmacol Sin. 2023 Mar;44 (3) :584-595.|Acta Pharmacol Sin. 2025 Jan;46 (1) :159-170.|Adv Mater. 2024 Apr 21:e2313097.|bioRxiv. 2024 September 07.|BMC Cancer. 2025 Jan 7;25 (1) :24.|Cancers. 2020 Aug 4;12 (8) :2169.|Cell Rep Med. 2024 Feb 20;5 (2) :101388.|Cell Rep Med. 2025 Apr 2:102053.|ChemMedChem. 2025 Oct 6;20 (19) :e202500429.|Drug Metab Dispos. 2025 Mar;53 (3) :100046.|EJHaem. 2025 Aug 30;6 (5) :e70140.|EMBO Mol Med. 2024 Nov;16 (11) :2856-2881.|Exp Cell Res. 2020 Aug 1;393 (1) :112054.|Exp Mol Med. 2025 Nov;57 (11) :2559-2573.|Int J Biol Macromol. 2025 Jan 9:139582.|Int J Biol Sci. 2022 Mar 21;18 (6) :2568-2582.|J Am Chem Soc. 2022 Jun 15;144 (23) :10407-10416.|J Control Release. 2024 Nov 12:376:1271-1287.|J Enzyme Inhib Med Chem. 2025 Dec;40 (1) :2518191.|J Exp Clin Cancer Res. 2025 Aug 5;44 (1) :228.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|J Pharm Pharmacol. 2022 Jan 5;74 (1) :41-56.|Light Sci Appl. 2024 Oct 31;13 (1) :304.|Mol Cell. 2024 Jun 18:S1097-2765 (24) 00447-7.|Nat Cell Biol. 2024 Jun;26 (6) :917-931.|Patent. US20240307414A1.|Pharm Dev Technol. 2021 Jul;26 (6) :673-681.|Pharmacol Res. 2024 May 9:204:107208.|Research Square Print. November 28th, 2022.|RSC Adv. 2025 Aug 15;15 (35) :28965-28983.|RSC Med Chem. 2025 Apr 30;16 (7) :3197-3212.|Talanta. 2024 Jul 1:274:125987.|University of California, Irvine. 2024.|bioRxiv. 2023 Jan 13.|BMC Cancer. 2021 Oct 13;21 (1) :1101.|Cell Oncol (Dordr) . 2020 Dec;43 (6) :1099-1116.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Drug Deliv. 2022 Dec;29 (1) :2561-2578.|Int J Mol Sci. 2025 Apr 17;26 (8) :3790.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Med Oncol. 2020 Nov 19;37 (12) :116.|Nat Commun. 2020 Apr 14;11 (1) :1792.|University of Bonn. 2025 Feb.

• CAS Number:

  [65271-80-9]